Informations générales
  • Catégorie de maladie Infections et infestations , Maladies de l'appareil respiratoire (hors cancer) (BASEC)
  • État du recrutement recrutement en cours (BASEC/ICTRP)
  • Lieu de l’étude
    Aarau, Bâle, Bellinzona, Berne, Chur, Fribourg, Genève, Lausanne, Luzern, St-Gall, Winterthur, Zurich
    (BASEC)
  • Responsable de l'étude PD Dr. Dr. med. Patrick M. Meyer Sauteur patrick.meyersauteur@kispi.uzh.ch (BASEC)
  • Source(s) de données BASEC: Importé de 24.03.2025 ICTRP: N/A
  • Date de mise à jour 24.03.2025 15:10
HumRes65033 | SNCTP000005900 | BASEC2023-01295

A randomized controlled study on the use of antibiotics in children with pneumonia caused by mycoplasma

  • Catégorie de maladie Infections et infestations , Maladies de l'appareil respiratoire (hors cancer) (BASEC)
  • État du recrutement recrutement en cours (BASEC/ICTRP)
  • Lieu de l’étude
    Aarau, Bâle, Bellinzona, Berne, Chur, Fribourg, Genève, Lausanne, Luzern, St-Gall, Winterthur, Zurich
    (BASEC)
  • Responsable de l'étude PD Dr. Dr. med. Patrick M. Meyer Sauteur patrick.meyersauteur@kispi.uzh.ch (BASEC)
  • Source(s) de données BASEC: Importé de 24.03.2025 ICTRP: N/A
  • Date de mise à jour 24.03.2025 15:10

Résumé de l'étude

In the MYTHIC Study, we want to find out whether the treatment of pneumonia caused by mycoplasma with antibiotics is really necessary. Pneumonia is caused by bacteria, viruses, or fungi. Antibiotic therapy is only effective against bacteria. Each antibiotic also works only against certain types of bacteria. Mycoplasmas (Mycoplasma pneumoniae) are one of the most common bacterial causes of pneumonia in children. The recommended antibiotics against mycoplasmas are macrolides, which are the second most commonly used antibiotics in children after penicillin antibiotics. However, the effectiveness of macrolides in children with mycoplasma pneumonia is unclear. The excessive use of macrolides has led to a global development of bacterial resistance to these antibiotics. Therefore, it is important to use antibiotics only when absolutely necessary. Based on clear evidence from previous studies, we assume that children receiving macrolides will take the same time to recover from mycoplasma infection as children receiving a placebo. The children will be closely monitored during the study, so participation in the study poses no risk to the children.

(BASEC)

Intervention étudiée

In this study, participants will be randomly assigned to two groups: Group 1 (experimental group) will receive a macrolide antibiotic and Group 2 (control group) will receive a placebo (medication without active ingredient). Neither the participants nor the investigators will know who has been assigned to which group. The idea is to minimize the influence on the results. Through these measures, we can objectively assess whether the placebo is not worse than the antibiotic. The study lasts 28 days and includes 2 additional examinations as well as 3 telephone check-ups.

(BASEC)

Maladie en cours d'investigation

A bacterial pneumonia is usually treated with antibiotics. Many antibiotics are no longer effective due to the development of bacterial resistance. In this study, we investigate whether the treatment of pneumonia caused by mycoplasmas with antibiotics is really necessary.

(BASEC)

Critères de participation
- Children and adolescents aged 3-17 years presenting to the emergency department with pneumonia - Clinical diagnosis of pneumonia AND fever >38°C AND tachypnea (respiratory rate above age-specific reference values) - Positive screening test for mycoplasma infection - Written informed consent (BASEC)

Critères d'exclusion
- Known intolerance to azithromycin - Underlying comorbidities: cystic fibrosis or other chronic lung diseases (excluding asthma), primary or secondary immunodeficiency, cardiovascular disease, or severe cerebral palsy or myasthenia gravis - History of recurrent pneumonia (two or more episodes) or severe pneumonia - Antibiotic treatment for mycoplasmas within the last 7 days - Transfer to intensive care directly from the emergency department - Inability to take oral medications - It is unlikely that parents will attend follow-up visits as part of the study and reliably complete questionnaires, e.g., due to language barriers or because they live far from the study site (BASEC)

Lieu de l’étude

Aarau, Bâle, Bellinzona, Berne, Chur, Fribourg, Genève, Lausanne, Luzern, St-Gall, Winterthur, Zurich

(BASEC)

non disponible

Sponsor

Christoph Berger - University Children's Hospital Zurich

(BASEC)

Contact pour plus d'informations sur l'étude

Personne de contact en Suisse

PD Dr. Dr. med. Patrick M. Meyer Sauteur

+41 44 266 78 96

patrick.meyersauteur@kispi.uzh.ch

University Children's Hospital Zurich

(BASEC)

Informations scientifiques

non disponible

Nom du comité d'éthique approbateur (pour les études multicentriques, uniquement le comité principal)

Commission cantonale de Zurich

(BASEC)

Date d'approbation du comité d'éthique

14.05.2024

(BASEC)


Identifiant de l'essai ICTRP
non disponible

Titre officiel (approuvé par le comité d'éthique)
A randomized controlled non-inferiority trial of placebo versus macrolide antibiotics for Mycoplasma pneumoniae infection in children with community-acquired pneumonia - MYTHIC Study (BASEC)

Titre académique
non disponible

Titre public
non disponible

Maladie en cours d'investigation
non disponible

Intervention étudiée
non disponible

Type d'essai
non disponible

Plan de l'étude
non disponible

Critères d'inclusion/exclusion
non disponible

non disponible

Critères d'évaluation principaux et secondaires
non disponible

non disponible

Date d'enregistrement
non disponible

Inclusion du premier participant
non disponible

Sponsors secondaires
non disponible

Contacts supplémentaires
non disponible

ID secondaires
non disponible

Résultats-Données individuelles des participants
non disponible

Informations complémentaires sur l'essai
non disponible


Résultats de l'essai

Résumé des résultats

non disponible

Lien vers les résultats dans le registre primaire

non disponible